Naiyer A. Rizvi

64.8k citations

275 papers · 15.0k indexed · 10 hit papers · h-index 61

Oncology top 0.05%
Pulmonary and Respiratory Medicine top 0.1%
Molecular Biology top 2%
Immunology top 0.5%
Cancer Research top 0.5%

Co-authors: Mark G. Kris Vincent A. Miller Scott Antonia Matthew D. Hellmann William Pao Gregory J. Riely Scott Gettinger Laura Q.M. Chow
Topics: Lung Cancer Treatments and Mutations (140 papers)Cancer Immunotherapy and Biomarkers (134 papers)Lung Cancer Research Studies (59 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: Nature Science Nature Medicine
Partner nations: United States Canada France

In The Last Decade

Naiyer A. Rizvi

267 papers receiving 14.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

2017 738 citations Diego Chowell, Luc G.T. Morris et al. Science profile →
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

2016 700 citations Matthew D. Hellmann, Naiyer A. Rizvi et al. profile →
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

2018 670 citations Matthew D. Hellmann, Mark M. Awad et al. profile →
Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer

2004 628 citations Vincent A. Miller, Mark G. Kris et al. Journal of Clinical Oncology profile →
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

2006 623 citations Gregory J. Riely, William Pao et al. Clinical Cancer Research profile →
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

2016 481 citations Sarah B. Goldberg, Ani Sarkis Balmanoukian et al. profile →
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy

2017 445 citations Nadeem Riaz, Vladimir Makarov et al. profile →
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

2020 425 citations Catherine A. Shu, Justin F. Gainor et al. profile →
Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 394 citations Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology profile →
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 350 citations Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Naiyer A. Rizvi

Since Specialization

Citations

This map shows the geographic impact of Naiyer A. Rizvi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naiyer A. Rizvi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naiyer A. Rizvi more than expected).

Fields of papers citing papers by Naiyer A. Rizvi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naiyer A. Rizvi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naiyer A. Rizvi. The network helps show where Naiyer A. Rizvi may publish in the future.

Co-authorship network of co-authors of Naiyer A. Rizvi

This figure shows the co-authorship network connecting the top 25 collaborators of Naiyer A. Rizvi. A scholar is included among the top collaborators of Naiyer A. Rizvi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naiyer A. Rizvi. Naiyer A. Rizvi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings 2024 ·Journal for ImmunoTherapy of Cancer ·Brian S. Henick,Peter D. Koch,Justin F. Gainor,Mark M. Awad,Codruța Chiuzan,(unknown),(unknown),(unknown),(unknown),(unknown),Anjali Saqi,Jessica M. Grindheim,Katja Schulze,Joshua Sonett,Naiyer A. Rizvi,Benjamin Izar,Alison M. Taylor,Catherine A. Shu	4
2	Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development 2023 ·Journal for ImmunoTherapy of Cancer ·Hussein A. Tawbi,Ryan J. Sullivan,David Feltquate,Theresa LaVallee,Naiyer A. Rizvi,Elad Sharon,Jeffrey A. Sosman,Harriet M. Kluger	7
3	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy 2023 ·Journal for ImmunoTherapy of Cancer ·Naiyer A. Rizvi,Foluso O. Ademuyiwa,Z. Alexander Cao,Helen X Chen,Robert L. Ferris,Sarah B. Goldberg,Matthew D. Hellmann,Ranee Mehra,Ina Rhee,Jong Chul Park,Harriet M. Kluger,Hussein A. Tawbi,Ryan J. Sullivan	24
4	Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory  CD19 expressing hematologic malignancies (NCT05665062) 2023 ·Cancer Research ·Maria Lia Palomba,Matthew Mei,Paolo F. Caimi,(unknown),Marco L. Davila,(unknown),(unknown),(unknown),Martin Oft,Paul‐Joseph Aspuria,(unknown),Navneet Ratti,Naiyer A. Rizvi,(unknown),Ran Reshef	3
5	First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors 2022 ·Journal for ImmunoTherapy of Cancer ·Omid Hamid,Alberto Chiappori,John A. Thompson,Toshihiko Doi,Siwen Hu‐Lieskovan,Ferry A.L.M. Eskens,Willeke Ros,Adi Diab,Jean‐Philippe Spano,Naiyer A. Rizvi,Jeffrey S. Wasser,Eric Angevin,Patrick A. Ott,Alison Forgie,Wenjing Yang,Cen Guo,Jeffrey Chou,Anthony B. El-Khoueiry	37
6	Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy 2022 ·Cancer Immunology Research ·(unknown),(unknown),Robert S. Washburn,Radomir Kratchmarov,Shana M. Coley,Anjali Saqi,(unknown),Jianhua Hu,Catherine A. Shu,Naiyer A. Rizvi,Brian S. Henick,Steven L. Reiner	13
7	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) 2021 ·Journal for ImmunoTherapy of Cancer ·Natasha B. Leighl,Mary W. Redman,Naiyer A. Rizvi,Fred R. Hirsch,Philip C. Mack,Lawrence H. Schwartz,James L. Wade,William Irvin,Sreekanth Reddy,Jeffrey Crawford,Jeffrey D. Bradley,Thomas E. Stinchcombe,Suresh S. Ramalingam,Jieling Miao,Katherine Minichiello,Roy S. Herbst,Vassiliki A. Papadimitrakopoulou,Karen Kelly,David R. Gandara	38
8	Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Bonnie S. Glisson,Rom S. Leidner,Robert L. Ferris,John D. Powderly,Naiyer A. Rizvi,Bhumsuk Keam,Reva Schneider,Sanjay Goel,James Ohr,(unknown),Yanan Zheng,Steven Eck,Matthew Gribbin,Katie Streicher,Danielle M. Townsley,Sandip Pravin Patel	63
9	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study 2020 ·Clinical Cancer Research ·Han Si,Michael Kuziora,Katie Quinn,Elena Helman,Jiabu Ye,Feng Liu,Urban Scheuring,Solange Peters,Naiyer A. Rizvi,Philip Z. Brohawn,Koustubh Ranade,Brandon W. Higgs,Kimberly C. Banks,Vikram K. Chand,Rajiv Raja	86
10	Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Ani Sarkis Balmanoukian,Jeffrey R. Infante,Raid Aljumaily,Aung Naing,Ashish V. Chintakuntlawar,Naiyer A. Rizvi,Helen J. Ross,Michael S. Gordon,Philip R. Mallinder,Nairouz Elgeioushi,Ignacio Ferreira González,Nathan Standifer,Jennifer Cann,Nicholas M. Durham,(unknown),Rakesh Kumar,Crystal S. Denlinger	40
11	Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors 2018 ·Clinical Cancer Research ·David M. Hyman,Naiyer A. Rizvi,Ronald B. Natale,Deborah K. Armstrong,Michael J. Birrer,Lawrence D. Recht,Efrat Dotan,Vicky Makker,Thomas Kaley,(unknown),Matthew Gribbin,Jennifer McDevitt,Dominic W. Lai,Mohammed M. Dar	38
12	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapybreakdown → 2017 ·Science ·Diego Chowell,Luc G.T. Morris,Claud Grigg,Jeffrey K. Weber,Robert Samstein,Vladimir Makarov,Fengshen Kuo,Sviatoslav M. Kendall,David Requena,Nadeem Riaz,Benjamin D. Greenbaum,James M. Carroll,Edward B. Garon,David M. Hyman,Ahmet Zehir,David B. Solit,Michael F. Berger,Ruhong Zhou,Naiyer A. Rizvi,Timothy A. Chan	738
13	Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches 2015 ·Clinical Cancer Research ·Alexander Drilon,Lu Wang,Maria E. Arcila,Sohail Balasubramanian,Joel Greenbowe,Jeffrey S. Ross,Phil Stephens,Doron Lipson,Vincent A. Miller,Mark G. Kris,Marc Ladanyi,Naiyer A. Rizvi	202
14	Genetics and immunology: reinvigorated 2015 ·OncoImmunology ·Alexandra Snyder,Vladimir Makarov,Matthew D. Hellmann,Naiyer A. Rizvi,Taha Merghoub,Jedd D. Wolchok,Timothy A. Chan	7
15	Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Patricia LoRusso,Pasi A. Jänne,Moacyr Oliveira,Naiyer A. Rizvi,Lisa Malburg,Vicki L. Keedy,Lorrin Yee,Catherine Copigneaux,Thore Hettmann,Chi‐Yuan Wu,Agnes Ang,Abdel‐Baset Halim,Robert A. Beckman,Darrin M. Beaupre,Jordan Berlin	74
16	Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker 2012 ·Clinical Cancer Research ·M. Catherine Pietanza,Kyuichi Kadota,Kety Huberman,Camelia S. Sima,John J. Fiore,(unknown),William D. Travis,Adriana Heguy,Michelle S. Ginsberg,Andrei I. Holodny,Timothy A. Chan,Naiyer A. Rizvi,Christopher G. Azzoli,Gregory J. Riely,Mark G. Kris,Lee M. Krug	122
17	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions 2012 ·Clinical Cancer Research ·Yoshiyuki Suehara,Maria E. Arcila,Lu Wang,Adnan Hasanovic,Daphne Ang,Tatsuo Ito,(unknown),Alexander Drilon,Udayan Guha,Valerie W. Rusch,Mark G. Kris,Maureen F. Zakowski,Naiyer A. Rizvi,Raya Khanin,Marc Ladanyi	132
18	A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development 2010 ·Clinical Cancer Research ·Binsheng Zhao,Geoffrey R. Oxnard,Chaya S. Moskowitz,Mark G. Kris,William Pao,Pingzhen Guo,Valerie W. Rusch,Marc Ladanyi,Naiyer A. Rizvi,Lawrence H. Schwartz	82
19	Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study 2009 ·Journal of Clinical Oncology ·Ronald B. Natale,David Bodkin,Ramaswamy Govindan,Bethany Sleckman,Naiyer A. Rizvi,(unknown),Paul Germonpré,Wilfried Eberhardt,Paul K. Stockman,Sarah J. Kennedy,Malcolm Ranson	194
20	A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations 2007 ·Molecular Cancer Therapeutics ·Naiyer A. Rizvi,Mark G. Kris,Vincent A. Miller,Lee M. Krug,(unknown),Afshin Dowlati,Kendrith M. Rowland,Margaret Tonda,(unknown),(unknown),(unknown),(unknown),S. Gadgeel	2

About Naiyer A. Rizvi

Naiyer A. Rizvi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 275 papers that have together received 15.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (140 papers), Cancer Immunotherapy and Biomarkers (134 papers) and Lung Cancer Research Studies (59 papers). The work is most often cited by research in Oncology (11.0k citations), Pulmonary and Respiratory Medicine (7.7k citations) and Cancer Research (2.2k citations). Naiyer A. Rizvi has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Mark G. Kris, Vincent A. Miller, Scott Antonia, Matthew D. Hellmann, William Pao, Gregory J. Riely, Scott Gettinger, Laura Q.M. Chow, Christopher G. Azzoli and Hossein Borghaei. Their work appears in journals such as Nature, Science and Nature Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact